BEIGENE LTD ADS (BGNE) Covered Calls

You can sell covered calls on BEIGENE LTD ADS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BGNE (prices last updated Wed 4:16 PM ET):

BEIGENE LTD ADS (BGNE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
126.28 -0.41 110.47 179.00 479K - 7.4B
Covered Calls For BEIGENE LTD ADS (BGNE)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 125 1.70 177.30 -29.5% -3589.2%
Nov 16 125 7.50 171.50 -27.1% -319.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands